In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.


The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

The relationship between dietary salt intake and blood pressure control in hypertensive individuals under antihypertensive treatment; 7 years observation

Session Lifestyle choices and blood pressure

Speaker Kazuto Ohno

Congress : ESC Congress 2018

  • Topic : hypertension
  • Sub-topic : Hypertension: Lifestyle Modification
  • Session type : Advances in Science
  • FP Number : 1413

Authors : K Ohno (Hamamatsu,JP), H Takase (Hamamatsu,JP), M Machii (Hamamatsu,JP), D Nonaka (Hamamatsu,JP), T Sugiura (Nagoya,JP), N Ohte (Nagoya,JP), Y Dohi (Seto,JP)

15 views

Authors:
K. Ohno1 , H. Takase1 , M. Machii1 , D. Nonaka1 , T. Sugiura2 , N. Ohte2 , Y. Dohi3 , 1Enshu Hospital - Hamamatsu - Japan , 2Nagoya City University Graduate School of Medical Sciences - Nagoya - Japan , 3Nagoya Gakuin University - Seto - Japan ,

Citation:
European Heart Journal ( 2018 ) 39 ( Supplement ), 267

Background: Excess salt intake is one of the most important causes of hypertension and salt restriction by lifestyle modification results in a reduction of blood pressure. Salt restriction is recommended as a key strategy in the management of hypertension and, thus, should be instructed for hypertensive patients under medical treatment.

Purpose: We investigated recent changes in dietary salt intake and blood pressure (BP) levels in hypertensive patients under antihypertensive treatment.

Methods: Total of 12422 hypertensive subjects (male 8814, mean age 64.6±9.2 year-old) under antihypertensive medications who visited our hospital for a physical checkup between 2010 and 2016 were enrolled. They were divided into 3 groups according to the number of antihypertensive drugs prescribed (1, 2 and ≥3 drugs). Cross-sectional analyses were performed using data in each year during the period and changes during the 7 years were investigated. Individual salt intake was estimated using a spot urine by a previously reported method.

Results: BP levels and the accomplishment rate of the target BP (<140/90mmHg) were improved during the 7 years (132.7±13.6/80.0±8.9 to 128.8±13.7/76.3±9.6 mmHg, 65.6 to 76.4%; respectively) without a significant difference among the groups. In contrast, individual salt intake was gradually increased in all groups (11.7±3.7 to 12.2±4.0, 11.9±3.7 to 12.7±3.9, and 12.2±3.9 to 12.9±4.1 g/day in 1, 2, and ≥3 drugs groups, respectively). Over all, the accomplishment rate of the target salt intake (<6g/day) was decreased with increasing the number of antihypertensive drugs (3.5, 2.8, and 2.3% in the groups with 1, 2, and ≥3 drugs, respectively). The accomplishment rate of the target BP was significantly higher in patients who achieved the target salt intake than in those who did not in all groups (Over all; 80.2 vs. 73.3%).

Conclusions: The control of BP in individuals under antihypertensive medications has been improved during the last 7 years. However, dietary salt intake has not been reduced and salt restriction has not been successfully achieved especially in hypertensive patients with multiple antihypertensive medications. Excess salt intake may induce resistance to antihypertensive treatment and, thus, increase the number of antihypertensive drugs for BP control.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members



Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are